Skip to content
PoliticalRepoPoliticalRepo

United States · Bill · HR

H.R. 916 (103rd)

Prescription Drug Prices Review Board Act of 1993

openUnited States· United States Congress· EN

Introduced

16 February 1993

Last action

27 July 1993 · Introduced

Status

Sponsor introductory remarks on measure. (CR E1889)

Sponsors

Rep. Stark, Fortney Pete [D-CA-13], Rep. Collins, Cardiss [D-IL-7], Sen. Sanders, Bernard [I-VT], Del. de Lugo, Ron [D-VI-At Large], Rep. Frank, Barney [D-MA-4], Rep. Barrett, Thomas M. [D-WI-5], Rep. LaFalce, John J. [D-NY-29], Rep. Martinez, Matthew G. [D-CA-31], Rep. Pelosi, Nancy [D-CA-11], Rep. Strickland, Ted [D-OH-6], Rep. Clyburn, James E. [D-SC-6], Rep. Owens, Major R. [D-NY-11], Rep. Sabo, Martin Olav [D-MN-5], Rep. Blackwell, Lucien E. [D-PA-2], Rep. Hastings, Alcee L. [D-FL-20], Rep. Furse, Elizabeth [D-OR-1], Rep. Collins, Barbara-Rose [D-MI-15], Rep. Kaptur, Marcy [D-OH-9], Rep. Evans, Lane [D-IL-17], Rep. Barlow, Tom [D-KY-1], Rep. Foglietta, Thomas M. [D-PA-1], Rep. Hall, Tony P. [D-OH-3], Rep. Flake, Floyd H. [D-NY-6], Rep. Baesler, Scotty [D-KY-6], Sen. Torricelli, Robert G. [D-NJ], Rep. DeFazio, Peter A. [D-OR-4], Rep. Slaughter, Louise McIntosh [D-NY-25], Rep. Miller, George [D-CA-11], Rep. Clayton, Eva M. [D-NC-1], Rep. Kleczka, Gerald D. [D-WI-4], Rep. Pastor, Ed [D-AZ-4], Rep. Gibbons, Sam [D-FL-11], Rep. Dellums, Ronald V. [D-CA-9], Rep. Washington, Craig A. [D-TX-18], Rescom. Romero-Barcelo, Carlos A. [D-PR-At Large], Rep. Velázquez, Nydia M. [D-NY-7]

Subjects

Healthcare, Taxation

Source updated

3 June 2026

Healthcare · Taxation

Official sourceDownload fileView documentsShare

Summary

Prescription Drug Prices Review Board Act of 1993 - Establishes in the Food and Drug Administration the Patented Medicine Prices Review Board which shall have the power to decrease the length of term of a prescription drug patent if, after notice and a hearing, it is found that the drug's price is excessive. Defines the term excessive price. Allows the Board to require the recapture of tax benefits provided to the patentee of an excessively priced drug.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 16 February 1993

    Introduced

    Referred to the House Committee on Energy and Commerce.

    Source: IntroReferral

  2. 16 February 1993

    Introduced

    Introduced in House

    Source: IntroReferral

  3. 16 February 1993

    Introduced

    Introduced in House

    Source: IntroReferral

  4. 17 February 1993

    Introduced

    Sponsor introductory remarks on measure. (CR H658-659)

    Source: IntroReferral

  5. 1 March 1993

    Referred

    Referred to the Subcommittee on Health and the Environment.

    Source: Committee

  6. 24 March 1993

    Introduced

    Sponsor introductory remarks on measure. (CR E760)

    Source: IntroReferral

  7. 5 May 1993

    Introduced

    Sponsor introductory remarks on measure. (CR E1152-1153)

    Source: IntroReferral

  8. 13 May 1993

    Introduced

    Sponsor introductory remarks on measure. (CR H2486)

    Source: IntroReferral

  9. 18 May 1993

    Introduced

    Sponsor introductory remarks on measure. (CR E1273)

    Source: IntroReferral

  10. 25 May 1993

    Introduced

    Sponsor introductory remarks on measure. (CR E1346)

    Source: IntroReferral

  11. 8 June 1993

    Introduced

    Sponsor introductory remarks on measure. (CR E1419-1420)

    Source: IntroReferral

  12. 14 June 1993

    Introduced

    Sponsor introductory remarks on measure. (CR E1486)

    Source: IntroReferral

  13. 16 June 1993

    Introduced

    Sponsor introductory remarks on measure. (CR E1532-1533)

    Source: IntroReferral

  14. 17 June 1993

    Introduced

    Sponsor introductory remarks on measure. (CR E1539)

    Source: IntroReferral

  15. 23 June 1993

    Introduced

    Sponsor introductory remarks on measure. (CR E1598)

    Source: IntroReferral

  16. 13 July 1993

    Introduced

    Sponsor introductory remarks on measure. (CR E1745-1746)

    Source: IntroReferral

  17. 14 July 1993

    Referred

    Referred to the Subcommittee on Intellectual Property and Judicial Administration.

    Source: Committee

  18. 27 July 1993

    Introduced

    Sponsor introductory remarks on measure. (CR E1889)

    Source: IntroReferral

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in House (text)

View fileDownload file

This file cannot be previewed here. Use View or Download.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House (text)

    Introduced in House · EN · 28 February 1994

    ViewDownloadOpen at official source

  • Introduced in House (PDF)

    Introduced in House · EN · 28 February 1994

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House

    summary · EN · 16 February 1993

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Related records

No cross-record relationships stored yet.

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.